Similar Posts
Study shows link between prostate drugs and reduced DBL risk
A study published in Neurology has shown a link between the use of α-1 blockers, a type of drug used to treat urinary symptoms in men with an enlarged prostate, and a lower risk of developing dementia with Lewy bodies (DBL), with a risk reduction of about 40% when compared with men taking other prostate…
Dementia care ‘transformed’ with circadian lighting system
WCS Care has implemented a retrofit circadian lighting solution that has measurably improved the wellbeing of residents living with dementia. The system WCS Care now have at Sycamores, a 1960s-built care home, mimics the natural progression of daylight, changing from bright white light (6,500K) in the day to warm, low, candlelight (2,200K) in the evening,…
Carers at crisis point
More than half of family carers of a person with dementia say that they have reached crisis point in the last year and one in five carers report that they have had to admit loved ones to A&E due to a lack of support. A survey of 1,000 people by Alzheimer’s Society heard that 54%…
NHS England publish data showing a record increase in dementia diagnosis
NHS England has published data showing that 506,549 people received a dementia diagnosis in July 2025, compared to 490,163 in July 2024. The new figures, which NHS England say are a record increase, were published as part of an announcement giving an example of how the NHS is using technology to help people live with…
The Carer’s Leave Act comes into effect in the UK
New legislation – The Carer’s Leave Act – has come into effect that enables unpaid carers to ask for up to five days leave from their employer every year without risking dismissal. Employees can take time off in full or half days, or in a whole block of five days. Emily Holzhausen OBE, Director of…
Funding announced for 14 Commercial Research Delivery Centres across England
£72m of funding has been announced to establish 14 new Commercial Research Delivery Centres (CRDCs) across England. The investment, beginning in April 2025 and running for 7 years, is awarded from the £400 million Voluntary Scheme for Branded Medicine Pricing, Access, Growth (VPAG) Investment Programme (VPAG is a partnership between the UK Government and the…